Earnings summaries and quarterly performance for GoodRx Holdings.
Executive leadership at GoodRx Holdings.
Board of directors at GoodRx Holdings.
AR
Agnes Rey-Giraud
Detailed
Director
CA
Christopher Adams
Detailed
Director
DD
Dipanjan Deb
Detailed
Director
DH
Douglas Hirsch
Detailed
Director
GM
Gregory Mondre
Detailed
Director
IT
Ian T. Clark
Detailed
Director
KJ
Kelly J. Kennedy
Detailed
Director
RE
Ronald E. Bruehlman
Detailed
Director
SW
Scott Wagner
Detailed
Co-Chairman & Director
Research analysts who have asked questions during GoodRx Holdings earnings calls.
CR
Charles Rhyee
TD Cowen
6 questions for GDRX
Also covers: AMWL, BTSG, CAH +18 more
LG
Lisa Gill
JPMorgan Chase & Co.
6 questions for GDRX
Also covers: AGL, CAH, CI +13 more
Daniel Grosslight
Citigroup
5 questions for GDRX
Also covers: AGL, CAH, COR +12 more
Jailendra Singh
Truist Securities
5 questions for GDRX
Also covers: ACCD, AGL, AMWL +16 more
JR
John Ransom
Raymond James
5 questions for GDRX
Also covers: ACHC, ADUS, ALHC +11 more
Michael Cherny
Leerink Partners
5 questions for GDRX
Also covers: ACCD, ALGN, CAH +18 more
Steven Valiquette
Mizuho
5 questions for GDRX
Also covers: ALGN, CAH, COR +12 more
Allen Lutz
Bank of America
4 questions for GDRX
Also covers: ACCD, CAH, COR +14 more
CH
Craig Hettenbach
Morgan Stanley
4 questions for GDRX
Also covers: ACCD, AMWL, ARDT +10 more
George Hill
Deutsche Bank
4 questions for GDRX
Also covers: AGL, CAH, CI +16 more
Scott Schoenhaus
KeyBanc Capital Markets
2 questions for GDRX
Also covers: ALIT, CERT, DOCS +8 more
SB
Stan Berenshteyn
Wells Fargo Securities
2 questions for GDRX
Also covers: AMWL, DOCS, HQY +2 more
SB
Stanislav Berenshteyn
Wells Fargo
2 questions for GDRX
Also covers: AMWL, DOCS, HCAT +3 more
Daniel Christopher Clark
Leerink Partners
1 question for GDRX
Also covers: DOCS, IDXX, ZTS
Eric Sheridan
Goldman Sachs
1 question for GDRX
Also covers: ABNB, ACVA, AMZN +42 more
Jenny Cao
Truist Securities
1 question for GDRX
Also covers: DOCS, VEEV
JJ
Jialin Jin
Morgan Stanley
1 question for GDRX
LH
Luismario Higuera
Citigroup Inc.
1 question for GDRX
Sean Dodge
RBC Capital Markets
1 question for GDRX
Also covers: CDMO, CTLT, EVH +10 more
SD
Stephanie Davis
Barclays
1 question for GDRX
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for GDRX.
GoodRx Announces Strategic Partnership with Surescripts and Highlights Growth Drivers
GDRX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- GoodRx announced a strategic partnership with Surescripts to launch "Script Corner," a mobile-enabled web application designed to provide patients with price transparency (including funded, GoodRx, and manufacturer program pricing) at the point of prescription writing.
- The company's manufacturer solutions business was a significant growth driver in 2025, performing upwards of 40% year-over-year.
- GoodRx launched condition-based subscription offerings in 2025 for ED, hair loss, and weight loss, including a partnership with Novo for GLP-1s, with early uptake meeting expectations.
- Management emphasized a commitment to cost discipline and managing EBITDA margins in 2026, while also considering elective spending to support growth initiatives.
- GoodRx has shifted its model to contract directly with nine of the top ten retailers to improve pharmacy margins and efficiency, particularly for branded drugs.
7 days ago
GoodRx Announces Surescripts Partnership and Highlights Growth in Key Segments
GDRX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- GoodRx announced a strategic partnership with Surescripts to launch "Script Corner," a mobile-enabled application designed to provide patients with price transparency (including funded, GoodRx, and other affordability programs) at the point of prescription writing to help reduce prescription abandonment. This initiative will initially be piloted with health systems.
- The Manufacturer Solutions segment is a significant driver of growth, achieving upwards of 40% year-over-year growth in 2025. This segment is considered a durable model and a material contributor to the company's overall growth.
- GoodRx launched condition-based subscription offerings in 2025 for ED, hair loss, and weight loss, focusing on branded therapies such as the Wegovy pill at $149. The company is pleased with the early performance of these programs.
- GoodRx remains committed to cost discipline and expanding EBITDA margins, having achieved this in 2024 and 2025. The company plans to continue this focus while potentially making elective investments for future growth, particularly in areas like weight loss subscriptions.
7 days ago
GoodRx Announces Surescripts Partnership and Discusses 2025 Performance
GDRX
New Projects/Investments
Product Launch
Guidance Update
- GoodRx announced a strategic partnership with Surescripts to launch "Script Corner", a new mobile-enabled application designed to provide prescription price transparency at the point of prescribing to patients. This initiative aims to reduce prescription abandonment and improve patient adherence.
- The company's manufacturer solutions business is a key growth driver, performing well in 2025 with upwards of 40% year-over-year growth anticipated.
- GoodRx launched condition-based subscription offerings for ED, hair loss, and weight loss in 2025, focusing on branded therapies for weight loss, and is very pleased with their performance.
- GoodRx expanded EBITDA margins in 2024 and 2025 and is committed to cost discipline, expecting to be in the longer-term target range for EBITDA margin in 2026, with potential elective spending for growth initiatives.
7 days ago
GoodRx offers Novo Nordisk's Wegovy pill at discounted cash price
GDRX
Product Launch
New Projects/Investments
- GoodRx has launched a program offering Novo Nordisk's newly FDA-approved Wegovy® pill (oral semaglutide) at a cash price of $149 per month for the two lowest doses (1.5mg and 4mg).
- This discounted pricing is available to eligible self-pay patients at over 70,000 pharmacies nationwide.
- The $149 per month price for the two lowest doses is valid until April 15, 2026, after which the 4mg dose will increase to $199 per month, with higher doses (9mg and 25mg) priced at $299 per month.
- GoodRx will also soon enable consumers to use GoodRx for Weight Loss to determine eligibility and obtain prescriptions for the Wegovy pill and other FDA-approved GLP-1 treatments.
Jan 5, 2026, 1:05 PM
GoodRx Launches Weight-Loss Telemedicine Service with GLP-1 Medication Pricing
GDRX
Product Launch
New Projects/Investments
- GoodRx has launched "GoodRx for Weight Loss," a new telemedicine subscription service providing access to FDA-approved GLP-1 weight loss medications.
- The subscription service is priced at $39 per month through January 2026, increasing to $119 per month thereafter.
- An introductory cash price of $199 per month is offered for the two lowest doses of Ozempic® and Wegovy® for first-time users through March 2026, with subsequent fills priced at $349 per month through March 31, 2026.
- GoodRx emphasizes its commitment to safety by exclusively connecting consumers with FDA-approved medications, rejecting compounded alternatives.
Nov 17, 2025, 1:50 PM
GoodRx Reports Q3 2025 Results with Strong Manufacturer Solutions Growth
GDRX
Earnings
Guidance Update
Share Buyback
- GoodRx reported Q3 2025 total revenue of $196 million, an approximate $1 million increase year-over-year, with adjusted EBITDA reaching $66.3 million, representing a 33.8% margin.
- Manufacturer solutions revenue grew by 54% year-over-year to $43.4 million in Q3 2025, driven by new and expanded partnerships, and is projected to grow approximately 35% for the full year 2025.
- The company maintained its full-year revenue guidance of at least $792 million and expects adjusted EBITDA growth of 2%-6% compared to 2024.
- Strategic initiatives included expanding partnerships with Novo Nordisk for Ozempic and Wegovy, Amgen for Repatha, and launching the RxSmartSaver counter solution at Kroger Pharmacies nationwide.
- GoodRx repurchased approximately 13.4 million shares for $61.6 million during Q3 2025, with $81.4 million remaining under its share repurchase program.
Nov 5, 2025, 1:00 PM
GoodRx Reports Q3 2025 Results
GDRX
Earnings
Guidance Update
Share Buyback
- GoodRx Holdings, Inc. reported Q3 2025 revenue of $196.0 million, a slight increase from $195.3 million in the comparable prior year period.
- For Q3 2025, net income was $1.1 million, down from $4.0 million in Q3 2024, while Adjusted EBITDA rose to $66.3 million from $65.0 million.
- The company maintained its full-year 2025 revenue and Adjusted EBITDA expectations, projecting an increase from $792.3 million (FY 2024) and a range of $265 million to $275 million, respectively.
- Pharma manufacturer solutions revenue grew significantly by 54% to $43.4 million in Q3 2025, leading to an increased full-year 2025 outlook for this segment to approximately 35% year-over-year growth.
- During Q3 2025, GoodRx repurchased 13.4 million shares for $61.6 million, with $81.4 million remaining under its authorized share repurchase program as of September 30, 2025.
Nov 4, 2025, 9:23 PM
GoodRx Launches Brand Medication Savings Program with Kroger
GDRX
Product Launch
New Projects/Investments
- GoodRx has launched its RxSmartSaver brand medication savings program at Kroger pharmacies nationwide, providing instant affordability for consumers.
- The program is now available in 2,200 Kroger pharmacies across 35 states, offering savings on key brand medications such as Dexcom G7, Humira® Biosimilar (ADBM), Lantus®, Ozempic®, and Wegovy®.
- This initiative is a turnkey solution for retail pharmacies, aiming to improve profitability and patient relationships, and follows an earlier launch with Hy-Vee with plans for further expansion.
Oct 1, 2025, 1:00 PM
GoodRx Reports Full-Year 2024 Financial Results and Issues 2025 Guidance
GDRX
Earnings
Guidance Update
Management Change
- GoodRx reported full-year 2024 revenue of $792.3 million, a 6% year-over-year increase, and Adjusted EBITDA of $260.2 million, up 20% from 2023.
- For full-year 2025, the company expects revenue between $810-$840 million and Adjusted EBITDA between $270-$286 million, reflecting approximately 4% and 7% growth at the midpoints, respectively.
- Manufacturer Solutions revenue increased 26% year-over-year to $107.2 million in 2024, with partnerships expanding to over 200 brands.
- The company's platform was used by almost 30 million consumers in 2024, an increase of nearly 5 million from 2023, and it estimates partner pharmacies' profitability in its book of business improved by over 20% per script in January 2025 compared to the prior year.
- Chris McGinnis was appointed as the new Chief Financial Officer.
Feb 27, 2025, 1:00 PM
GoodRx Highlights Strong Q2 2021 Performance and Strategic Growth
GDRX
Revenue Acceleration/Inflection
New Projects/Investments
- GoodRx reported $631 million in LTM Revenue for 2Q21, demonstrating 43% year-over-year revenue growth.
- The company achieved 7.5 million+ consumers in its prescription-related offerings by June 2021, including 6,002K Monthly Active Consumers (up 36% YoY) and 1,051K subscription plan users (up 86% YoY).
- GoodRx's Pharma Manufacturer Solutions, identified as its fastest-growing offering, achieved ~3X YTD year-over-year revenue growth and 150%+ Net Revenue Retention as of 2Q21, working with 19 of the top 20 pharma manufacturers.
- The platform maintains high consumer engagement with ~20 million monthly visitors and 80%+ repeat activity.
Sep 30, 2021, 6:30 PM
Quarterly earnings call transcripts for GoodRx Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more